Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 6/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132193 | 0.72 | LMNA (0.51) | LMNA | |
| SCHEMBL4832295 | 0.72 | UTS2R (0.52) | EGFRCSF1RKDRPDE4B | |
| SCHEMBL5122523 | 0.70 | ABCG2 (0.59) | LMNA | |
| SCHEMBL5129444 | 0.69 | GAK (0.57) | EGFRKDR | |
| SCHEMBL5126891 | 0.69 | GAK (0.38) | EGFRITKKDR | |
| SCHEMBL15525264 | 0.67 | TRPV1 (0.43) | BCL6KIT | |
| SCHEMBL6334528 | 0.63 | LMNA (0.51) | LMNA | |
| SCHEMBL2727828 | 0.62 | RAPGEF4 (0.46) | BCL6TDO2IDO1RAPGEF4 | |
| SCHEMBL16585428 | 0.61 | TSHR (0.41) | LMNA | |
| SCHEMBL9097313 | 0.59 | CSNK2A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | BCL6 4863/4885TDO2 1923/4885IDO1 1576/4885 |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | BCL6 4863/4885TDO2 1923/4885IDO1 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.